SCOLR Pha	rma, Inc.							
Form 4 October 03, 2	2005							
					OMB APPROVAL			
FORM	OMB 3235-0287 Number:							
Check thi if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pur inue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section						
(Print or Type F	Responses)							
1. Name and Address of Reporting Person <u>*</u> CAUDILL RANDALL L W			Issuer Name and Ticker or Tradi bol OLR Pharma, Inc. [DDD]	Issuer	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First) (Middle) 3. E	ate of Earliest Transaction	(Check	(Check an applicable)			
C/O SCOLR PHARMA, INC., 3625- 132ND AVENUE SE SUITE 300			nth/Day/Year) 30/2005	X_ Director Officer (give below)	Officer (give title Other (specify			
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year) BELLEVUE, WA 98006				 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
DELLEVUI	E, WA 98000			Person				
(City)	(State)	(Zip)	Table I - Non-Derivative Secur	ities Acquired, Disposed of	or Beneficially Owned			
	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date any (Month/Day/Yo	Code Disposed of (D) ar) (Instr. 8) (Instr. 3, 4 and 5 (A) or	Securities For Beneficially (I 5) Owned (I	Ownership7. Nature oform: DirectIndirectO) or IndirectBeneficial)Ownershipnstr. 4)(Instr. 4)			
Reminder: Rep	ort on a separate line	e for each class o	f securities beneficially owned dir	rectly or indirectly.				
	I		Persons wi information required to	no respond to the collect n contained in this form a respond unless the forn currently valid OMB cont	are not (9-02) 1			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8.
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	nof Derivative	Expiration Date	Underlying Securities	D
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	S

Edgar Filing: SCOLR Pharma, Inc. - Form 4

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr.	8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy) (1)	\$ 2.05	09/30/2005		А		1,832		09/30/2005	09/29/2015	Common Stock	1,832

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
CAUDILL RANDALL L W C/O SCOLR PHARMA, INC. 3625- 132ND AVENUE SE SUITE 300 BELLEVUE, WA 98006	Х						
Signatures							
/s/ Randall L-W. Caudill. by Daniel O. W Attorney	ilds,	10	10/03/2005				
<u>**</u> Signature of Reporting Person			Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- In accordance with the Company's 2004 Equity Incentive Plan, Mr. Caudill elected to receive stock options (with an exercise price of (1) 50% of the average closing price of the common stock on the 10 trading days preceding the date of grant) in lieu of cash compensation for services as a director.
- (2) Not Applicable.

Ś

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(]